¼¼°èÀÇ ÆéƼµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå
Peptide Microarray
»óǰÄÚµå : 1791768
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 168 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,274,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,824,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ÆéƼµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀåÀº 2030³â±îÁö 4¾ï 4,510¸¸ ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 3¾ï 3,060¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ÆéƼµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 5.1%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 4¾ï 4,510¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ½Ã¾àÀº CAGR 5.4%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 2¾ï 8,830¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±â±â ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 4.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 8,690¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 5.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÆéƼµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀåÀº 2024³â¿¡´Â 8,690¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 7,190¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 5.0%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 4.8%¿Í 4.3%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.1%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ÆéƼµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹À̶õ?

ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â ÆéŸÀ̵å-´Ü¹éÁú »óÈ£ÀÛ¿ëÀÇ ÇÏÀ̽º·çDz ½ºÅ©¸®´×, ¹ÙÀÌ¿À¸¶Ä¿ ½Äº°, ½Å¾à°³¹ß¿¡ »ç¿ëµÇ´Â ±â¼úÀÔ´Ï´Ù. ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â ½½¶óÀÌµå ±Û¶ó½º³ª ¸âºê·¹ÀÎ µîÀÇ °íü Ç¥¸é¿¡ Áú¼­Á¤¿¬ÇÏ°Ô °íÁ¤µÈ ÆéŸÀ̵åÀÇ ¹è¿­·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÆéŸÀ̵å´Â ƯÁ¤ ¿¡ÇÇÅäÇÁ, ´ÜÆí ¶Ç´Â ¿¬±¸ÀÚ°¡ °ü½É ÀÖ´Â ÀüÀå ´Ü¹éÁúÀ» ³ªÅ¸³¾ ¼ö ÀÖ½À´Ï´Ù. ÀÌ °úÁ¤¿¡¼­ ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹À̸¦ Ç×ü, ´Ü¹éÁú, Ç÷û µîÀÇ »ý¹°ÇÐÀû »ùÇÿ¡ ³ëÃâ½ÃÄÑ ÆéŸÀ̵å¿Í »ý¹°ÇÐÀû ºÐÀÚ¿ÍÀÇ »óÈ£ÀÛ¿ëÀ» °ËÃâÇÕ´Ï´Ù. À̸¦ ÅëÇØ ¿¬±¸ÀÚµéÀº ÆéŸÀ̵åÀÇ °áÇÕ ÆÐÅϰú ´Ü¹éÁú °£ »óÈ£ÀÛ¿ëÀ» Á¶»çÇϰí, ´Ù¾çÇÑ Áúº´ ¹× Ä¡·á Ç¥ÀûÀÇ ÀáÀçÀû ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â º¹ÀâÇÑ »ýü ½Ã½ºÅÛÀ» ºÐ¼®ÇÏ°í ÆéŸÀÌµå »óÈ£ÀÛ¿ëÀ» ´ë±Ô¸ð·Î ½ºÅ©¸®´×ÇÒ ¼ö ÀÖ´Â °­·ÂÇÑ µµ±¸·Î µîÀåÇß½À´Ï´Ù. ´Ü¹éÁú, DNA, ±âŸ »ýü ºÐÀÚ¿Í »óÈ£ÀÛ¿ëÇÏ´Â ÆéŸÀ̵åÀÇ Æ¯À̼ºÀ» ÀÌ¿ëÇÏ¿©, ÀÌ·¯ÇÑ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â ¸é¿ªÇÐ, ¾Ï ¿¬±¸, °¨¿°º´ ¿¬±¸, ¸ÂÃãÀÇ·á µîÀÇ ºÐ¾ß¿¡¼­ ³Î¸® Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¼ö¹é, ¼öõ °³ÀÇ ÆéŸÀ̵带 µ¿½Ã¿¡ ºÐ¼®ÇÒ ¼ö Àֱ⠶§¹®¿¡ ºÐÀÚ °£ »óÈ£ÀÛ¿ë¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ °³¿ä¸¦ ¾òÀ» ¼ö ÀÖ¾î ½Å¾à, ¹é½Å, Áø´Ü µµ±¸ÀÇ ¹ß°ßÀ» °¡¼ÓÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀåÀÌ È®´ëµÇ´Â ÀÌÀ¯´Â?

ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀåÀº °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¾Ï ¹× ÀÚ°¡¸é¿ªÁúȯ µîÀÇ Áúº´ À¯º´·ü Áõ°¡, ÇÏÀ̽º·çDz ±â¼úÀÇ ¹ßÀüÀ¸·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â °³ÀÎÀÇ À¯ÀüÀû üÁúÀ̳ª ƯÁ¤ Áúº´ Ư¼º¿¡ µû¶ó Ä¡·á¸¦ ¸ÂÃãÈ­Çϱâ À§ÇÑ °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â °³Àκ° ¸ÂÃã Ä¡·á °èȹÀÇ ÁöħÀÌ µÉ ¼ö ÀÖ´Â ÀáÀçÀû ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. ƯÈ÷ Á¾¾çÇÐÀ̳ª ¸é¿ªÄ¡·áÀÇ °æ¿ì, Á¤È®ÇÑ Å¸°ÙÆÃÀº Ä¡·á È¿°ú¸¦ ±Ø´ëÈ­ÇÏ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

¾Ï, ´ç´¢º´, ÀÚ°¡¸é¿ªÁúȯ µî ¸¸¼ºÁúȯ Áõ°¡µµ ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Áúº´Àº º¹ÀâÇÑ Áø´Ü°ú Ä¡·á°¡ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹À¸¸ç, ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö°ú Ä¡·á Ç¥Àû ¹ß±¼À» À§ÇÑ °­·ÂÇÑ µµ±¸°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. ÆéŸÀÌµå »óÈ£ÀÛ¿ë°ú ´Ü¹éÁú Ȱ¼º¿¡ ´ëÇÑ °íÇØ»óµµ µ¥ÀÌÅ͸¦ Á¦°øÇÔÀ¸·Î½á, ÀÌ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â Áúº´ÀÇ Á¶±â ¹ß°ß, Áúº´ ÁøÇà ¸ð´ÏÅ͸µ, Ä¡·á È¿°ú Æò°¡¿¡ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ, ¸¹Àº ¼öÀÇ ÆéŸÀ̵带 º´·Ä·Î ºü¸£°Ô ½ºÅ©¸®´×ÇÒ ¼ö Àֱ⠶§¹®¿¡ ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â »õ·Î¿î Áø´Ü ¹× Ä¡·á¹ýÀ» °³¹ßÇÏ´Â ¿¬±¸Àڵ鿡°Ô ¸Å·ÂÀûÀÎ ¼±ÅÃÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

°íó¸® ±â¼úÀÇ ¹ßÀüµµ ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÃֽŠÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ Ç÷§ÆûÀº È¿¼Ò °áÇÕ ¸é¿ª ÈíÂø ÃøÁ¤¹ý(ELISA)À̳ª ¿þ½ºÅÏ ºí·ÎÆÃ°ú °°Àº ±âÁ¸ ±â¼ú¿¡ ¼Ò¿äµÇ´Â ½Ã°£°ú ºñ¿ëÀ» Àý°¨ÇÏ°í º¸´Ù ºü¸£°í Á¤È®ÇÑ ºÐ¼®À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS) ¹× CRISPR ±â¹Ý ½Ã½ºÅÛ µî ´Ù¸¥ ±â¼ú°úÀÇ ÅëÇÕÀ» ÅëÇØ ±× ÀÀ¿ë ¹üÀ§°¡ ´õ¿í È®´ëµÇ¾î ºÐÀÚ»ý¹°ÇÐ, ½Å¾à°³¹ß ¹× Àӻ󿬱¸¸¦ À§ÇÑ ´Ù¿ëµµ·Î °­·ÂÇÑ µµ±¸°¡ µÇ¾ú½À´Ï´Ù.

ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌÀÇ ¹Ì·¡¸¦ Á¿ìÇÒ ÁÖ¿ä µ¿ÇâÀº?

ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå Àü¸ÁÀº ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ¿Í ´Ù¸¥ ±â¼ú°úÀÇ ÅëÇÕ ¹ßÀü, ºÐ¼® ¹Î°¨µµ ¹× ´ÙÁßÈ­ ¹ßÀü, ÀÚµ¿È­ ¹× ¼ÒÇüÈ­¿¡ ´ëÇÑ °ü½É Áõ°¡ µî ¸î °¡Áö ÁÖ¿ä Æ®·»µå¿¡ ÀÇÇØ Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. °¡Àå ÁÖ¸ñÇÒ ¸¸ÇÑ Æ®·»µå Áß Çϳª´Â ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ¿Í Â÷¼¼´ë ¿°±â¼­¿­ºÐ¼®±â(NGS), Áú·®ºÐ¼®, CRISPR ±â¹Ý ½Ã½ºÅÛ°úÀÇ ÅëÇÕÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÅëÇÕ Ç÷§ÆûÀº ÆéŸÀÌµå »óÈ£ÀÛ¿ë¿¡ ´ëÇÑ º¸´Ù Á¾ÇÕÀûÀ̰í Á¤È®ÇÑ ºÐ¼®À» °¡´ÉÇÏ°Ô Çϰí, »õ·Î¿î Ä¡·á Ç¥Àû°ú ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¹ß°ßÀ» ÃËÁøÇÕ´Ï´Ù. ¿¬±¸ÀÚµéÀÌ º¹ÀâÇÑ »ý¹°ÇÐÀû ½Ã½ºÅÛÀ» ÀÌÇØÇϰíÀÚ ÇÏ´Â °¡¿îµ¥, ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹À̸¦ ´Ù¸¥ ÷´Ü ±â¼ú°ú °áÇÕÇÏ¸é º¸´Ù Á¤±³ÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â µ¥ÀÌÅ͸¦ ¾òÀ» ¼ö ÀÖ¾î ÇâÈÄ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

ºÐ¼® °¨µµ¿Í ´ÙÁßÈ­ÀÇ ¹ßÀüµµ ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä Æ®·»µåÀÔ´Ï´Ù. ¿¬±¸ °³¹ßÀº ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌÀÇ ¹Î°¨µµ¿Í ƯÀ̼ºÀ» Çâ»ó½ÃŰ´Â »õ·Î¿î ±â¼úÀ» °³¹ßÇÏ¿©, ³·Àº Á¸Àç·®ÀÇ ¹ÙÀÌ¿À¸¶Ä¿¿Í ´Ü¹éÁú »óÈ£ÀÛ¿ëÀÇ ¹Ì¹¦ÇÑ º¯È­¸¦ °¨ÁöÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. ÇϳªÀÇ Ä¨¿¡¼­ ¿©·¯ Ÿ°Ù°ú »ýü ºÐÀÚ¸¦ µ¿½Ã¿¡ ºÐ¼®ÇÒ ¼ö ÀÖ´Â ¸ÖƼÇ÷º½º ±â´ÉÀ¸·Î ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÇÇèÀÇ Ã³¸®·®À» Çâ»ó½ÃÄ×½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº °á°úÀÇ Á¤È®µµ¸¦ Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó ÇÊ¿äÇÑ ½Ã·á¿Í ½Ã¾àÀÇ ¾çÀ» ÁÙ¿© ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹À̸¦ ´ë±Ô¸ð ¿¬±¸¿¡ º¸´Ù ºñ¿ë È¿À²ÀûÀ̰í È¿À²ÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù.

¶Ç ´Ù¸¥ Áß¿äÇÑ Æ®·»µå´Â ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ±â¼úÀÇ ÀÚµ¿È­ ¹× ¼ÒÇüÈ­¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. °í󸮷® ½ºÅ©¸®´× ¹× ´ë±Ô¸ð ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó, »ç¶÷ÀÇ °³ÀÔÀ» ÃÖ¼ÒÈ­Çϸ鼭 ´ë·®ÀÇ ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ µ¥ÀÌÅ͸¦ ó¸®ÇÒ ¼ö ÀÖ´Â ÀÚµ¿È­ ½Ã½ºÅÛ °³¹ßÀÌ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¶ÀÌÅ©·Î¾î·¹ÀÌÀÇ ¼ÒÇüÈ­·Î ÀÎÇØ º¸´Ù ÄÄÆÑÆ®Çϰí Àú·ÅÇÑ Ç÷§Æû °³¹ßÀÌ °¡´ÉÇØÁü¿¡ µû¶ó ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹À̰¡ ¿¬±¸½Ç°ú ÀÓ»óÇöÀå¿¡ º¸´Ù Ä£¼÷ÇÏ°Ô ´Ù°¡°¥ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÚµ¿È­µÈ ÇÏÀ̽º·çDz ½Ã½ºÅÛÀ» ÅëÇØ ¿¬±¸ÀÚµéÀº ´ë±Ô¸ð ½ºÅ©¸®´×À» ¼öÇàÇÏ°í ´õ ¸¹Àº ÆéŸÀ̵带 ´õ ªÀº ½Ã°£¿¡ ºÐ¼®ÇÒ ¼ö ÀÖ¾î ½Å¾à°³¹ß°ú ¸ÂÃãÀÇ·á¿¡ ´ëÇÑ ³ë·ÂÀ» ´õ¿í °¡¼ÓÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀåÀÇ ¼ºÀå ÃËÁø¿äÀÎÀº?

ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀåÀÇ ¼ºÀåÀº Á¤¹ÐÀÇ·áÀÇ ¹ßÀü, ½Å¼ÓÇÑ Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Áúº´ ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ ¿¬±¸ È®´ë µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. °³ÀÎÀÇ À¯ÀüÀÚ ¹× ºÐÀÚ ÇÁ·ÎÆÄÀÏ¿¡ µû¶ó Ä¡·á¸¦ Á¶Á¤ÇÏ´Â Á¤¹ÐÀÇ·á´Â ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀåÀÇ Áß¿äÇÑ ÃËÁøÁ¦ÀÔ´Ï´Ù. °³Àκ° ¸ÂÃãÄ¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó, Á¤È®ÇÏ°í ³ôÀº 󸮷®À» °¡Áø ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö¹ýÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°ÇÏ°í °ËÁõÇÏ´Â °­·ÂÇÑ µµ±¸·Î, ƯÈ÷ Á¾¾çÇÐ ¹× ÀÚ°¡¸é¿ªÁúȯÀÇ Ç¥ÀûÄ¡·áÁ¦ °³¹ß¿¡ ÀÖ¾î ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

¼¼°èÀûÀ¸·Î Áõ°¡ÇÏ´Â °Ç°­ ºÎ´ã¿¡ ´ëóÇϱâ À§ÇÑ ½Å¼ÓÇÑ Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ´Â °Íµµ ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â ¾Ï, °¨¿° µî Áúº´ÀÇ Á¶±â ¹ß°ß¿¡ ƯÈ÷ À¯¿ëÇϸç, Á¶±â °³ÀÔÀ» ÅëÇØ ȯÀÚÀÇ ¿¹Èĸ¦ Å©°Ô °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â »ý¹°ÇÐÀû »ùÇÿ¡¼­ Áúº´ ƯÀÌÀû ¹ÙÀÌ¿À¸¶Ä¿¸¦ °ËÃâÇÒ ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á ±âÁ¸ ¹æ½Ä¿¡ ºñÇØ ´õ ºü¸£°í È¿À²ÀûÀÎ Áúº´ Áø´Ü ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. Áúº´ ¸¶Ä¿¸¦ ½Å¼ÓÇÏ°Ô ½Äº°ÇÒ ¼ö ÀÖ´Â ÀÌ ´É·ÂÀº Àû½Ã¿¡ Áø´ÜÇÏ¿© ´õ ³ªÀº ȯÀÚ °ü¸® ¹× Ä¡·á Àü·«À¸·Î À̾îÁö´Â ÀÓ»ó ÇöÀå¿¡¼­ ÇʼöÀûÀÔ´Ï´Ù.

ÆéŸÀ̵å ÇÕ¼º, ¾î·¹ÀÌ Á¦ÀÛ ¹× ºÐ¼® ±â¼úÀÇ ¹ßÀüµµ ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÇϳªÀÇ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ Ä¨¿¡¼­ ´Ù¼öÀÇ ÆéŸÀ̵带 ÇÕ¼ºÇÒ ¼ö ÀÖ°Ô µÊ¿¡ µû¶ó, ´Ü¹éÁú »óÈ£ÀÛ¿ë°ú ºÐÀÚ °æ·Î¿¡ ´ëÇÑ º¸´Ù Á¾ÇÕÀûÀÌ°í »ó¼¼ÇÑ ºÐ¼®ÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ, µ¥ÀÌÅÍ ºÐ¼® ¼ÒÇÁÆ®¿þ¾î¿Í °è»ê µµ±¸ÀÇ °³¼±À¸·Î ¿¬±¸ÀÚµéÀº ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ µ¥ÀÌÅ͸¦ º¸´Ù È¿°úÀûÀ¸·Î ÇØ¼®ÇÒ ¼ö ÀÖ°Ô µÇ¾î, ½Å¾à °³¹ß ¹× Áúº´ ¿¬±¸¿¡ ÀÖ¾î ÀÌ ±â¼úÀÇ °¡Ä¡°¡ ´õ¿í ³ô¾ÆÁ³½À´Ï´Ù. ºÐÀÚ»ý¹°ÇÐ ºÐ¾ß°¡ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó ÆéŸÀÌµå ¸¶ÀÌÅ©·Î¾î·¹ÀÌ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(½Ã¾à, ±â±â, ¼­ºñ½º), ¿ëµµ(Áúȯ Áø´Ü ¿ëµµ, ´Ü¹éÁú ±â´É ºÐ¼® ¿ëµµ, Ç×ü Ư¼º ÇØ¼® ¿ëµµ, Drug Discovery ¿ëµµ), ÃÖÁ¾ ¿ëµµ(Á¦¾à ¹× ¹ÙÀÌ¿À ±â¾÷ ÃÖÁ¾ ¿ëµµ, º´¿ø ¹× Ŭ¸®´Ð ÃÖÁ¾ ¿ëµµ, Áø´Ü¼¾ÅÍ ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Peptide Microarray Market to Reach US$445.1 Million by 2030

The global market for Peptide Microarray estimated at US$330.6 Million in the year 2024, is expected to reach US$445.1 Million by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Reagents, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$288.3 Million by the end of the analysis period. Growth in the Instruments segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$86.9 Million While China is Forecast to Grow at 5.0% CAGR

The Peptide Microarray market in the U.S. is estimated at US$86.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$71.9 Million by the year 2030 trailing a CAGR of 5.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.8% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Peptide Microarray Market - Key Trends & Drivers Summarized

What Is a Peptide Microarray and How Does It Work?

A peptide microarray is a technology used for high-throughput screening of peptide-protein interactions, biomarker identification, and drug discovery. It consists of an array of peptides that are immobilized on a solid surface, typically a glass slide or membrane, in an orderly fashion. These peptides can represent specific epitopes, fragments, or full-length proteins that researchers are interested in studying. The process involves exposing the peptide microarray to biological samples, such as antibodies, proteins, or serum, and then detecting the interactions between the peptides and the biological molecules. This allows researchers to investigate peptide binding patterns, protein-protein interactions, and identify potential biomarkers for various diseases or therapeutic targets.

Peptide microarrays have emerged as a powerful tool for analyzing complex biological systems and enabling large-scale screening of peptide interactions. By leveraging the specificity of peptides to interact with proteins, DNA, or other biomolecules, these microarrays are widely used in areas such as immunology, cancer research, infectious disease research, and personalized medicine. The ability to analyze hundreds or even thousands of peptides simultaneously provides a comprehensive overview of molecular interactions, accelerating the discovery of new drugs, vaccines, and diagnostic tools.

Why Is the Peptide Microarray Market Expanding?

The peptide microarray market is expanding due to the growing demand for personalized medicine, the increasing prevalence of diseases like cancer and autoimmune disorders, and advancements in high-throughput technologies. One of the key factors contributing to market growth is the rising interest in personalized medicine, which aims to tailor treatments based on an individual’s genetic makeup and specific disease characteristics. Peptide microarrays enable the identification of potential biomarkers that can guide personalized treatment plans, especially in oncology and immunotherapy, where precise targeting of therapies is essential for maximizing efficacy and minimizing side effects.

The increasing incidence of chronic diseases such as cancer, diabetes, and autoimmune conditions is another significant driver for the growth of peptide microarrays. These diseases often require complex diagnostics and treatments, and peptide microarrays offer a powerful tool for biomarker discovery and the identification of therapeutic targets. By providing high-resolution data on peptide interactions and protein activity, these microarrays can aid in the early detection of diseases, monitoring disease progression, and assessing the effectiveness of treatments. Additionally, the ability to quickly screen large numbers of peptides in parallel makes peptide microarrays an attractive option for researchers developing new diagnostics and therapies.

Advancements in high-throughput technologies are also contributing to the growth of the peptide microarray market. Modern peptide microarray platforms allow for faster and more accurate analysis, reducing the time and cost involved in traditional techniques such as enzyme-linked immunosorbent assays (ELISAs) and western blotting. The integration of peptide microarrays with other technologies, such as next-generation sequencing (NGS) and CRISPR-based systems, is further expanding their applications, making them a versatile and powerful tool for molecular biology, drug discovery, and clinical research.

What Key Trends Are Shaping the Future of Peptide Microarrays?

The future of the peptide microarray market is being shaped by several key trends, including the increasing integration of peptide microarrays with other technologies, advancements in assay sensitivity and multiplexing, and the growing focus on automation and miniaturization. One of the most notable trends is the integration of peptide microarrays with next-generation sequencing (NGS), mass spectrometry, and CRISPR-based systems. These integrated platforms allow for more comprehensive and accurate analyses of peptide interactions, facilitating the discovery of novel therapeutic targets and biomarkers. As researchers seek to understand complex biological systems, combining peptide microarrays with other cutting-edge technologies is expected to lead to more advanced and reliable data, driving the market's future growth.

Advancements in assay sensitivity and multiplexing are also key trends that will shape the peptide microarray market. Researchers are developing new techniques that improve the sensitivity and specificity of peptide microarrays, allowing for the detection of low-abundance biomarkers or subtle changes in protein interactions. Multiplexing capabilities, which enable the simultaneous analysis of multiple targets or biomolecules on a single chip, are increasing the throughput of peptide microarray experiments. These advancements not only enhance the precision of results but also reduce the amount of sample and reagents required, making peptide microarrays more cost-effective and efficient for large-scale studies.

Another key trend is the growing focus on automation and miniaturization in peptide microarray technologies. As demand for high-throughput screening and large-scale biomarker discovery grows, there is a push to develop automated systems that can handle large volumes of peptide microarray data with minimal human intervention. Miniaturization of microarrays is also enabling the development of more compact and affordable platforms, making peptide microarrays more accessible to research labs and clinical settings. Automated, high-throughput systems will allow researchers to conduct large-scale screenings and analyze a wider array of peptides in a shorter amount of time, further accelerating drug discovery and personalized medicine efforts.

What Are the Key Drivers of Growth in the Peptide Microarray Market?

The growth in the peptide microarray market is driven by several factors, including advancements in precision medicine, the increasing need for rapid diagnostic tools, and the expansion of research into disease mechanisms. Precision medicine, which tailors treatments based on individual genetic and molecular profiles, is a significant driver for the peptide microarray market. As the demand for personalized therapies continues to rise, the need for accurate and high-throughput biomarker discovery methods becomes more important. Peptide microarrays provide a powerful tool for identifying and validating biomarkers, making them crucial in the development of targeted therapies, especially in oncology and autoimmune diseases.

The increasing need for rapid diagnostic tools to address the growing global health burden is another key driver of the peptide microarray market. Peptide microarrays are particularly valuable in the early detection of diseases such as cancer and infectious diseases, where early intervention can significantly improve patient outcomes. By enabling the detection of disease-specific biomarkers in biological samples, peptide microarrays offer a faster, more efficient way to diagnose diseases compared to traditional methods. This ability to rapidly identify disease markers is essential in clinical settings, where timely diagnoses can lead to better patient management and treatment strategies.

Advances in peptide synthesis, array production, and assay technologies are also contributing to the growth of the peptide microarray market. The ability to synthesize a large number of peptides on a single microarray chip has made it possible to conduct more comprehensive and detailed analyses of protein interactions and molecular pathways. Additionally, improvements in data analysis software and computational tools are enabling researchers to interpret peptide microarray data more effectively, further increasing the technology's value in drug discovery and disease research. As the field of molecular biology continues to evolve, the demand for peptide microarrays will likely increase, driving further market growth.

SCOPE OF STUDY:

The report analyzes the Peptide Microarray market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Reagents, Instruments, Services); Application (Disease Diagnostics Application, Protein Functional Analysis Application, Antibody Characterization Application, Drug Discovery Application); End-Use (Pharma & Biotech Companies End-Use, Hospitals & Clinics End-Use, Diagnostic Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â